Allergan had a good third quarter, with sales up by 10.5 percent to $1,098.2 million over the same period last year. That represents an increase of 8.6 percent at constant currencies. In eye care pharmaceuticals, revenues grew by 11.5 percent to $510.4 million, or 9.1 percent at constant currencies. The ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.